as Alnylam Picks Inex s Platform Over Protiva s Despite Co-Authoring Study Supporting It in RNAi

Alnylam signed the deal with Inex even though the technology is at the center of a legal thicket that raises doubts about who actually owns the rights to license it. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.